Andaman7 Seeks $5m to Continue Investment in Pioneering Technology
Investors offered a unique opportunity to help secure growth of world-leading patient-mediated research platform.
Liège, Belgium, and Washington DC, USA- March 26th, 2025: Andaman7, the platform transforming healthcare communications and bridging the gap between patients and researchers, is seeking investment to reach the next milestones in its ground-breaking journey.
Led by patient advocate Vincent Keunen, Andaman7 offers a unique combination of a powerful personal health record (PHR) for patients and a next-generation clinical research platform (CRP) for the industry. It empowers patients to securely collect and control their health data in a free user-friendly app, creating a decentralized ecosystem that unlocks real-world data access for clinical research.
Pharma needs real partnership with patients. Andaman7’s PHR has been downloaded in 50 countries and is available in the 20 most spoken languages in the world. Having invested more than $10m in PHR and CRP tech, Andaman7 is integrated with 80% of US health systems. It has demonstrated repeatability in clinical trials and other studies and is using artificial intelligence (AI) capabilities to empower patients worldwide. At least two years ahead of its nearest competitors, the value of Andaman7 has been recognised by key opinion leaders:
● You guys, you've got it all figured out. You are the future of clinical research. ICON
● A7 has no competition, no one is doing that today. You are pioneering “patient mediated research”. Johnson & Johnson
Now, Andaman7 is seeking investment to:
● Get $1m licenses with top life science customers over the next two years.
● Finalise three AI features for its already innovative platform.
● Become the number one health data interoperability player in Europe and the rest of the world during predicted market growth.
Andaman7 Founder & CEO, Vincent Keunen, said: “Andaman7 is experiencing high demand, with a strong pipeline worth several million Euros. There is a growing market for real-world data collection, and we need funding to scale and fully capture the momentum we have already built.
“The US has already greatly improved interoperability – as evidenced by the fact that 85% of US patients can now access their data. The EU is behind but looks set to catch up within two to five years. Andaman7 is already at the forefront in the EU, having been used by HL7 and the EU Commission as a demonstration of what is to come. We want to continue to build on what is being developed in Europe, and the rest of the world, and be ready for when the market explodes.
“We are also in the process of adding three powerful features which will revolutionize our already innovative platform even further and create better data for industry. An investment in Andaman7 is not just a sound financial decision, it also demonstrates to the wider industry that you are at the forefront of patient-mediated research.”
To find out more about how you could be part of the next step in Andaman7’s exciting journey contact founders@andaman7.com.
-ENDS-
About Vincent Keunen
Vincent Keunen is the founder and CEO of Andaman7. Previously, he developed numerous medical IT systems (a secure data exchange platform used by more than 90% of Belgian hospitals and family doctors, and a prevention EHR, managing today close to 1 million patients). Vincent was also the CIO of success-story Lampiris and was awarded the CIO of the year prize for his work there. When Vincent was diagnosed with leukaemia in 2007, and his 10-year-old son was diagnosed with bone cancer 3 months later, he decided to use his software engineering skills to provide all patients with a tool to manage their health information on their smartphone. That platform can now be used to improve medical research by collecting RWE (Real World Evidence) and PRO (Patient Reported Outcomes) while facilitating telemedicine, remote patient monitoring, and continuity of care.
Find out more about Vincent Keunen’s personal story at http://bit.ly/a7vkblogen.
About Andaman7
Andaman7 is a Belgian-American eHealth company and was created to significantly improve communication and efficiency in collaboration between healthcare actors: patients, doctors, and researchers. Andaman7’s unique "security by design and privacy by default" architecture does not store medical data in the cloud. Data is only stored on mobile devices and exchanged in a distributed peer to peer method. Andaman7‘s patient centric health intermediation platform is designed to help patients better manage their health data, enable outcome measurement for pharma and research, and support disease management for hospitals and doctors.
With particular strengths in RWE, QoL, and PRO studies, Andaman7 is in use by citizens of over 50 countries and available in 20 languages. Andaman7 is compliant with GDPR and HIPAA and is validated FDA 21 CFR part 11 and EU Annex 11 for clinical trials. For more detail, visit https://www.andaman7.com/